Entropy Neurodynamics Limited · ASX:ENP
Entropy Neurodynamics — TechKnow 2026 Investor Roadshow
18 slides from Entropy Neurodynamics's conference presentation, Jul 27, 2026
Slide 1: ASX Announcement: Techknow Invest Roadshow presentation
ASX Announcement ASX : ENP 27 July 2026 Techknow Invest Roadshow presentation Melbourne, Australia – Entropy Neurodynamics Limited (‘Entropy Neurodynamics’ or the ‘Company’) (ASX: ENP), a clinical-stage biotechnology company, advises that that Chief Executive Officer, Mr Jason Carroll, will present
Slide 2: Risks associated with Psilocin and forward-looking information
provides shareholders with the opportunity to elect communication methods to electronic only. This can be done via the following steps: • Go to investor.automic.com.au • If you're an existing user, log in with your username and password • If you're a new user, click ‘register’, select ‘Entropy Neuro
Slide 3: Achieving Leadership in the treatment of neuropsychiatry disorders
5 ENTROPY: {<) NEURODYNAMICS* ) Achieving Leadership in the treatment of neuropsychiatry disorders TechKnow 2026 Investor Roadshow July 2026 This presentation has been authorised for release by the Board of Entropy Neurodynamics Limited
Slide 4: Disclaimers
Disclaimers ‘The information contained in this presentation (the “Presentation”) has been prepared by Tryp Therapeutics inc. (*Tryp" or the “Company"] and contains information pertaining to the business, operations and assets ofthe Company. The information contained in this Presentation (a) s provid
Slide 5: Overview and Investment Thesis
Overview and Investment Thesis 1. A unique next-generation psychedelic platform: Lead asset, TRP-8803 is a proprietary IV-infusion platform therapy that delivers a rapid, precise, consistent and reversible treatment experience for patients TRP-8803 overcomes the critical limitations of oral psychede
Slide 6: Corporate Overview
Corporate Overview Corporate Snapshot ASX code: ENP Shares on issue: 1.6Bn Market capitalisation: AUSss8.8m (at $0.036 per share) Cash at bank: (at 30 June 2026) AUSS.6m se only Debt: (Exercisable before 29 May 2027) XX Board of Directors Non-Executive Chairman Additional funding accessible through
Slide 7: Compelling treatment-resistant data from previous oral psilocybin studies
Compelling treatment-resistant data from previous oral psilocybin studies ag underpin confidence in TRP-8803 as a precision therapy platform Fibromyalgia (FM) Binge Eating Disorder (BED) Irritable Bowel Syndrome (IBS) Chronic Pain associated with 4 body sectors or more University of Michigan 100% of
Slide 8: TRP-8803 has been specifically designed to remove the barriers to therapy
TRP-8803 has been specifically designed to remove the barriers to therapy @) TRP-8803 : A Precision approach in Neuropsychiatry IV-infused Psilocin Oral Psilocybin * Short treatment duration ~8-10 hours of 1-2 hours Quick onset of psychedelic state (~15 minutes) Precision targeting of drug hight edb
Slide 9: Variability and inconsistency of oral psilocybin vs TRP-8803
Variability and inconsistency of oral psilocybin vs TRP-8803 ORAL PSILOCYBIN = || (-25ng/ml) | Therapeutic g* : : Window £— 2 i Lower 8 Threshold 10 (15 ng/ml) a 0 2 8 Sub-therapeutic == Therapeutic ransition Therapeutic Window (~15-25 ng/m! © _ Time toreach therapeutic zone: Highly variable <= Time
Slide 10: Phase 2 TRP-8803 trial in treatment-resistant Binge-Eating Disorder (BED)
Phase 2 TRP-8803 trial in treatment-resistant Binge-Eating Disorder (BED) Overview: Phase 2, open-label clinical trial in collaboration with Swinburne University Objective: Evaluate the safety, tolerability and preliminary efficacy of TRP-8803 Therapy: TRP-8803 (IV-infused psilocin) Cohort: 12 chron
Slide 11: Landmark trial results validate TRP-8803 as a potential treatment
Landmark trial results validate TRP-8803 as a potential treatment 50% 100% 74% REMISSION MEANINGFUL WEEKLY BINGE > 5 CLINICAL CLINICALLY REDUCTION IN o iD IMPROVEMENT EATING EPISODES TRP-8803 delivered 50% remission in treatment-resistant BED and clinical improvement in 100% of patients Clinical saf
Slide 12: Additional, highly compelling findings
Additional, highly compelling findings D> Cc oO 57% reduction 63% Clinical Global 58% Results from i in Depression | improvement Impression reduction in cohort 2 (12 (PHQ-9) in quality of improvement Anxiety patients) life of 33% (GAD-7) expected Q4 CY26 Large, multi-domain therapeutic gains rarely
Slide 13: Strategic significance
Strategic significance Early results demonstrates that TRP-8803 delivers rapid, reproducible and clinically meaningful therapeutic benefit in patients with treatment-resistant BED. > Cc (o) Most importantly: ® esults validate oS as a differentiated precision-controlled psychedelic platform Yn Resul
Slide 14: Global pharma chasing differentiated Phase assets on minimal patient data
Global pharma chasing differentiated Phase 2 assets on minimal patient data AbbVie tunes in to Gilgamesh's story, inking $1.2B deal for psychedelic program AUGUST 25, 2025: USS1.2Bn transaction for a pharmaceutical small molecule, bretisilocin (Phase 2a stage) Strong signal from Abbsvie, the leading
Slide 15: Aggressive absorption of global IP rights
Aggressive absorption of global IP rights Patent applications and trade secrets based on novel methods for manufacturing, formulation, dosing and treatment of specific disease indications have been filed for all major global pharmaceutical markets * Provisional patent filed in March 2021 (US 63/161,
Slide 16: TRP-8803 has three major growth categories for commercialisation
TRP-8803 has three major growth categories for commercialisation *) Maximum efficacy of standard of care: ENP’s results to date: Total potential patient population (US-only): Infusion infrastructure availability & readiness: ENTROPY NEURODYNAMICS: Advancing Psychedelic Scie Psychiatry 40-60% across
Slide 17: Multiple pending value catalysts
Multiple pending value catalysts aD TRP-8803 64 patient multi-indication study launch (Swinburne University) Imminent = Commencement of cohort 2 dosing in Phase 2 BED trial with Swinburne University Q3 CY26 co Commencement and completion of patient recruitment in multi-indication study Q3-Q4 CY26 Co
Slide 18: Contact
ENTROPY NEURODYNAMICS" CONTACT Jason Carroll Chief Executive Officer jcarroll@tryptherapeutics.com Website: www.entropyneurodynamics.com Henry Jordan Six Degrees Investor Relations henry.jordan@sdir.com.au Socials: X (Twitter) @tryptherapeutic
Entropy Neurodynamics — TechKnow 2026 Investor Roadshow on 6ix